15 June 2022 in Journal of Neuroinflammation
Background: Microglia are the endogenous immune cells of the brain and act as sensors of pathology to maintain brain homeostasis and eliminate potential threats. In Alzheimer's disease (AD), toxic amyloid beta (Aβ) accumulates in the brain and forms stiff plaques. In late-onset AD accounting for 95% of all cases, this is thought to be due to reduced clearance of Aβ. Human genome-wide association studies and animal models suggest that reduced clearance results from aberrant function of microglia. While the impact of neurochemical pathways on microglia had been broadly studied, mechanical receptors regulating microglial functions remain largely unexplored. Methods: Here we showed that a mechanotransduction ion channel, PIEZO1, is expressed and functional in human and mouse microglia. We used a small molecule agonist, Yoda1, to study how activation of PIEZO1 affects AD-related functions in human induced pluripotent stem cell (iPSC)-derived microglia-like cells (iMGL) under controlled laboratory experiments. Cell survival, metabolism, phagocytosis and lysosomal activity were assessed using real-time functional assays. To evaluate the effect of activation of PIEZO1 in vivo, 5-month-old 5xFAD male mice were infused daily with Yoda1 for two weeks through intracranial cannulas. Microglial Iba1 expression and Aβ pathology were quantified with immunohistochemistry and confocal microscopy. Published human and mouse AD datasets were used for in-depth analysis of PIEZO1 gene expression and related pathways in microglial subpopulations. Results: We show that PIEZO1 orchestrates Aβ clearance by enhancing microglial survival, phagocytosis, and lysosomal activity. Aβ inhibited PIEZO1-mediated calcium transients, whereas activation of PIEZO1 with a selective agonist, Yoda1, improved microglial phagocytosis resulting in Aβ clearance both in human and mouse models of AD. Moreover, PIEZO1 expression was associated with a unique microglial transcriptional phenotype in AD as indicated by assessment of cellular metabolism, and human and mouse single-cell datasets. Conclusion: These results indicate that the compromised function of microglia in AD could be improved by controlled activation of PIEZO1 channels resulting in alleviated Aβ burden. Pharmacological regulation of these mechanoreceptors in microglia could represent a novel therapeutic paradigm for AD.
15 March 2024 in Nature Cardiovascular Research
Discovery of meningeal lymphatic vessels (LVs) in the dura mater, also known as dural LVs (dLVs) that depend on vascular endothelial growth factor C expression, has raised interest in their possible involvement in Alzheimer’s disease (AD). Here we find that in the APdE9 and 5xFAD mouse models of AD, dural amyloid-β (Aβ) is confined to blood vessels and dLV morphology or function is not altered. The induction of sustained dLV atrophy or hyperplasia in the AD mice by blocking or overexpressing vascular endothelial growth factor C, impaired or improved, respectively, macromolecular cerebrospinal fluid (CSF) drainage to cervical lymph nodes. Yet, sustained manipulation of dLVs did not significantly alter the overall brain Aβ plaque load. Moreover, dLV atrophy did not alter the behavioral phenotypes of the AD mice, but it improved CSF-to-blood drainage. Our results indicate that sustained dLV manipulation does not affect Aβ deposition in the brain and that compensatory mechanisms promote CSF clearance.
18 June 2025 in Alzheimer's & Dementia
INTRODUCTION: Red blood cells (RBCs) are crucial for oxygen delivery to active tissues and endure significant mechanical forces in the microcirculatory bed. The enrichment of mechanosensitive Piezo1 channels, linked to the cytoskeleton, aids RBCs in navigating the narrow capillaries. In Alzheimer's disease (AD), impaired brain microcirculation may necessitate enhanced Piezo1 function in RBCs.METHODS: With micropipette aspiration and flow cytometry technics, we evaluated, using the specific Piezo1 agonist Yoda1, AD‐related alterations in the biomechanical properties of RBCs from cognitively healthy patients (HC) and individuals with mild cognitive impairment (MCI) and AD.RESULTS: We show that beta‐amyloid (Aβ) peptides alter the biomechanical properties of RBCs. We observed significantly higher Yoda1‐induced calcium responses in RBCs in individuals with MCI and AD compared to RBCs from age‐matched HC.CONCLUSION: Our data suggest that Yoda1‐induced Ca2+ flux through Piezo1 channel emerges as a measurable indicator associated with and improves the detection of AD‐related dementia.Highlights: Piezo1 channels aid the navigation of red blood cells (RBCs) through narrow capillaries. Alzheimer's disease (AD) patients show increased Yoda1‐induced activation of Piezo1 in RBCs. Incorporation of Yoda1‐induced Piezo1 readouts improved the detection of AD‐related dementia. Investigating Yoda1‐induced Piezo1 activity associated with early AD.
25 March 2026 in Epilepsia Open
Objective: Temporal lobe epilepsy (TLE) is characterized by recurrent seizures originating usually from the hippocampus, and approximately one‐third of TLE patients remain refractory to pharmacological interventions. Surgical resection offers a potential cure for refractory TLE cases, with approximately 70% achieving seizure freedom. Still, the pathogenesis of TLE remains poorly understood. Electrophysiological characterization of the resected tissue with microelectrode arrays (MEAs) can help reveal the pathogenesis of TLE, but the commercially available MEAs cover only a small part of the hippocampal cross‐section. The objective here is to develop a MEA that can cover a significant area of a human hippocampal slice to help understand the electrophysiology of TLE pathogenesis. Methods: The custom MEA, entitled Hippo‐MEA, was designed to have 60 round electrodes, each 60 μm in diameter, in an area of 5.6 mm × 5.6 mm. The titanium nitride‐coated electrodes were deposited on borosilicate glass using ion beam‐assisted e‐beam deposition (IBAD) process. Hippo‐MEA's sample chamber, named Sample Cup, was designed large enough to hold a human hippocampal slice. Hippocampal samples were obtained from patients undergoing neurosurgical tissue resection for TLE treatment and sliced to 300 μm thick sections for Hippo‐MEA recording. Data from the Hippo‐MEA were recorded using the commercially available MEA2100‐Mini‐system. Cellular composition of the recording area was analyzed with immunohistochemistry (IHC). Results: Extracellular action potentials (EAPs) and local field potentials (LFPs) were successfully recorded from acute human hippocampal slices. Activity was mainly localized to the dentate gyrus, whereas the CA regions found sclerotic and gliotic in IHC analysis showed little to no activity. Significance: Hippo‐MEA is compatible with a commercially available and widely used data acquisition system and enables recording of EAPs and LFPs across several regions of human hippocampal tissue. This enables Hippo‐MEA, in combination with other methods, to help discover the neurophysiological mechanisms of TLE. Plain Language Summary: In some cases of temporal lobe epilepsy (TLE), the only treatment option is to surgically remove a part of the brain, including a structure known as the hippocampus, which is often the source of the electrical epileptic activity. Understanding hippocampal function is important to understanding the reasons behind TLE and designing the surgeries. Microelectrode arrays (MEAs) are a tool for recording the electrical function of tissues. Here we present a new MEA, named Hippo‐MEA, that is big enough to measure a cross‐section of the human hippocampus.
27 February 2025 in bioRxiv
Temporal lobe epilepsy (TLE) is a prevalent neurological disorder characterized by recurrent seizures originating from the cortex, amygdala and especially hippocampus. While two-thirds of TLE patients achieve seizure control through medication, approximately one-third remain refractory to pharmacological interventions. For these individuals, surgical resection offers a potential curative option, with approximately 70% achieving seizure freedom. However, the pathogenesis of TLE remains incompletely understood, necessitating further investigation. Therefore, resected brain tissue obtained during the surgery provides a valuable resource for ex vivo study of pathological neuronal activity. Currently, microelectrode array (MEA) technology is widely used for electrophysiological studies. However, commercially available MEAs are limited in their ability to record from large tissue samples, such as an entire hippocampal section. To address this limitation, we have developed a custom MEA and sample chamber compatible with commercially available headstages. This system enables recording of extracellular action potentials (EAPs) and local field potentials (LFPs) across human hippocampal tissue, providing a valuable tool for investigating the neurophysiological mechanisms underlying TLE. Graphical Highlights: A custom microelectrode array and chamber created for human hippocampal slices The custom array recorded action potentials from human hippocampal slices The custom array recorded local field potentials from human hippocampal slices